A Potent Blood-Brain Barrier-Permeable Mutant IDH1 Inhibitor Suppresses the Growth of Glioblastoma with IDH1 Mutation in a Patient-Derived Orthotopic Xenograft Model.

导出原文传递

翻译打印收藏纠错

作者： Yukino,Machida ^[1] ; Makoto,Nakagawa ^[2] ; Hironori,Matsunaga ^[1] ; Masayuki,Yamaguchi ^[3] ; Yoko,Ogawara ^[4] ; Yutaka,Shima ^[5] ; Kazutsune,Yamagata ^[6] ; Takuo,Katsumoto ^[1] ; Ayuna,Hattori ^[1] ; Masato,Itoh ^[1] ; Takahiko,Seki ^[1] ; Yumi,Nishiya ^[1] ; Koichi,Nakamura ^[5] ; Kanae,Suzuki ^[5] ; Tomoki,Imaoka ^[7] ; Daichi,Baba ^[7] ; Makoto,Suzuki ^[7] ; Oltea,Sampetrean ^[7] ; Hideyuki,Saya ^[8] ; Koichi,Ichimura ^[9] ; Issay,Kitabayashi ^[10]

作者单位： Division of Hematological Malignancy, National Cancer Center Research Institute, Tokyo, Japan. ^[1] Department of Veterinary Pathology, Nippon Veterinary and Life Science University, Tokyo, Japan. ^[2] Department of Orthopaedic Surgery, Graduate School of Medical Sciences, Kyushu University, Fukuoka, Japan. ^[3] Division of Musculoskeletal Oncology, National Cancer Center Hospital, Tokyo, Japan. ^[4] Oncology Laboratories, Daiichi Sankyo Co., Ltd., Tokyo, Japan. ^[5] Division of Functional Imaging, Research Center for Innovative Oncology, National Cancer Center Hospital East, Chiba, Japan. ^[6] Drug Metabolism and Pharmacokinetics Research Laboratories, Daiichi Sankyo Co., Ltd., Tokyo, Japan. ^[7] Post-Marketing Regulatory Affairs Department, Daiichi Sankyo Co., Ltd., Tokyo, Japan. ^[8] Structure-Based Drug Design Group, Organic Synthesis Department, Daiichi Sankyo RD Novare Co., Ltd., Tokyo, Japan. ^[9] Division of Gene Regulation, School of Medicine, Keio University, Tokyo, Japan. ^[10] Division of Brain Tumor Translational Research, National Cancer Center Research Institute, Tokyo, Japan. ^[11] Division of Hematological Malignancy, National Cancer Center Research Institute, Tokyo, Japan. ikitabay@ncc.go.jp. ^[12]